Merck’s efforts to combine its PD-1 blockbuster Keytruda with an experimental LAG-3 inhibitor hit a stumbling block Wednesday ...
Within the span of a week, the FDA gave the green light to another drug for the rare condition Niemann-Pick disease type C in ...
Bristol Myers Squibb said Wednesday that they are discontinuing enrollment in the Phase 3 KarMMa-9 study investigating Abecma in patients with newly diagnosed multiple myeloma. 2seventy CEO Chip Baird ...
Italian gene therapy startup nabs $52M for rare genetic disease that Moderna is working on
Genespire patched together a €46.6 million (about $52 million) funding round to get its lead gene therapy into the clinic in ...
Amgen released data from two pivotal trials on Tuesday that showed its experimental drug rocatinlimab succeeded in a Phase 3 ...
Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its ...
The FDA's Oncologic Drugs Advisory Committee will meet Thursday to discuss whether several immune checkpoint inhibitor drugs ...
Sen. Bernie Sanders (I-VT) told Novo Nordisk CEO Lars Fruergaard Jørgensen that three major pharmacy benefit managers have ...
Biotech company SIGA Technologies has fired Chief Medical Officer Jay Varma, days after the publication of secret recordings ...
Wave Life Sciences said new Phase 2 biomarker data for its exon-skipping therapy are promising for certain patients with ...
PCI Pharma Services is pouring $365 million to expand its US and Irish footprint for commercial and clinical packaging of ...
Plus, news about Adaptimmune, Roche, LifT BioSciences, VerImmune, and Revance Therapeutics: Capricor Therapeutics to file Duchenne cardiomyopathy treatment with the FDA: The San Diego-based biotech in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback